1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Australian Stock Exchange  -  01:54 2022-08-12 am EDT
0.0120 AUD    0.00%
08/02Hexima Managing Director, CEO Steps Down
MT
08/01Hexima Limited Announces Management Changes
CI
07/21HEXIMA : Quarterly Activities Report and Appendix 4C - Jun-22 Qtr
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide

06/23/2022 | 09:32pm EDT

On June 24, 2022, Hexima Limited announced that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete.


© S&P Capital IQ 2022
All news about HEXIMA LIMITED
08/02Hexima Managing Director, CEO Steps Down
MT
08/01Hexima Limited Announces Management Changes
CI
07/21HEXIMA : Quarterly Activities Report and Appendix 4C - Jun-22 Qtr
PU
07/10Hexima Limited Announces Phase II Results of Pezadeftide
CI
06/24Australian Shares Jump on IT Boost Amid Bargain Hunting
MT
06/23Hexima to Conduct Detailed Review of Pezadeftide Phase 2 Trial Data after 'Inconclusive..
MT
06/23Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide
CI
04/28HEXIMA : ShareCafe Presentation
PU
04/27HEXIMA : Notification regarding unquoted securities - HXL
PU
04/04HEXIMA : Investor Webinar on Today
PU
More news
Financials
Sales 2022 - - -
Net income 2022 -9,30 M -6,61 M -6,61 M
Net cash 2022 41,5 M 29,5 M 29,5 M
P/E ratio 2022 -0,21x
Yield 2022 -
Capitalization 2,00 M 1,42 M 1,42 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees -
Free-Float 47,6%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,01 AUD
Average target price 0,75 AUD
Spread / Average Target 6 150%
EPS Revisions
Managers and Directors
Nicole Louise van der Weerden Chief Executive Officer, COO & Executive Director
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Scott Robertson Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-97.11%1
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068